Spruce Biosciences, Inc. (SPRB)
US — Healthcare Sector
Automate Your Wheel Strategy on SPRB
With Tiblio's Option Bot, you can configure your own wheel strategy including SPRB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SPRB
- Rev/Share 0.0662
- Book/Share 0.3487
- PB 0.189
- Debt/Equity 0.1308
- CurrentRatio 1.9517
- ROIC -3.3478
- MktCap 2783043.0
- FreeCF/Share -1.2227
- PFCF -0.0518
- PE -0.0699
- Debt/Assets 0.0633
- DivYield 0
- ROE -1.069
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | SPRB | JMP Securities | Mkt Outperform | Market Perform | -- | -- | Dec. 11, 2024 |
| Downgrade | SPRB | Oppenheimer | Outperform | Perform | -- | -- | Dec. 11, 2024 |
News
About Spruce Biosciences, Inc. (SPRB)
- IPO Date 2020-10-09
- Website https://www.sprucebiosciences.com
- Industry Biotechnology
- CEO Dr. Javier Szwarcberg M.D., M.P.H.
- Employees 20
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.